Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2000
11/23/2000WO2000023100A3 Genes and proteins predictive and therapeutic for renal disease and associated disorders
11/23/2000WO2000021575A3 Calpain inhibitors and their applications
11/23/2000WO2000020450A3 Calcium channel alpha-2/delta gene
11/23/2000WO2000019978A3 Compositions and methods for enhancing receptor-mediated cellular internalization
11/23/2000WO2000017369A3 Alzheimer's disease secretase
11/23/2000WO2000015790A3 Leptin induced genes
11/23/2000WO2000012740A3 Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
11/23/2000WO2000009666A3 Differentiation of non-insulin producing cells into insulin producing cells by glp-1 or exendin-4 and uses thereof
11/23/2000WO2000008157A3 Human anion transporter genes atnov
11/23/2000WO2000007545A3 Apoptosis proteins
11/23/2000WO2000004863A3 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
11/23/2000WO1999045952A3 Method of preventing the death of retinal neurons and treating ocular diseases
11/23/2000WO1999004775A3 Method of treating dopaminergic and gaba-nergic disorders
11/23/2000DE19929802A1 Product containing deodorized marine collagen, useful e.g. as hemostatic sponge or drug carrier, optionally crosslinked to improve mechanical properties
11/23/2000DE19923027A1 Verfahren zur Inaktivierung von Viren A method of inactivating viruses
11/23/2000DE19922753A1 New instant enzyme formulation, useful as animal feed supplement, made by agglomerating a water-soluble powdered carrier by spraying on a solution of an enzyme preparation or a binder
11/23/2000DE19921537A1 Treating carbohydrate metabolism disorders, especially diabetes, comprises activating insulin-secreting b-cells using glucagon-related peptide, glucose-dependent insulinotropic polypeptide, exendin-4 or related drugs
11/23/2000DE10002892A1 New immunodominant peptides from actin, useful for diagnosis and treatment of type I autoimmune hepatitis
11/23/2000CA2767116A1 Adjuvant combination formulations
11/23/2000CA2623458A1 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
11/23/2000CA2505617A1 Modified secretin and method of synthesizing thereof
11/23/2000CA2501421A1 Long lasting exendin-4
11/23/2000CA2499211A1 Modified peptides yy and conjugates thereof
11/23/2000CA2374108A1 Anionic polymers as toxin binders and antibacterial agents
11/23/2000CA2374053A1 Secreted polypeptides and corresponding polynucleotides
11/23/2000CA2374045A1 Compositions isolated from skin cells and methods for their use
11/23/2000CA2374013A1 Protein a based binding domains with desirable activities
11/23/2000CA2373938A1 Compositions and methods for treating cell proliferation disorders
11/23/2000CA2373681A1 Pharmaceutical compositions for treating angina and/or anginal equivalents, and kit relating thereto
11/23/2000CA2373616A1 Tm4sf receptors
11/23/2000CA2373231A1 Extracellular signaling molecules
11/23/2000CA2373191A1 Full-length molecules expressed in human tissues
11/23/2000CA2372926A1 143 human secreted proteins
11/23/2000CA2372549A1 Ox2 receptor homologs
11/23/2000CA2372541A1 Sphingosine kinase enzyme
11/23/2000CA2372441A1 Instant formulations of enzymes, used for animal feed
11/23/2000CA2372435A1 Recombinant human mannan-binding lectin
11/23/2000CA2372393A1 Novel proteins with insulin-like activity useful in the treatment of diabetes
11/23/2000CA2372392A1 Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same
11/23/2000CA2372338A1 Long lasting fusion peptide inhibitors of viral infection
11/23/2000CA2372304A1 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins
11/23/2000CA2372200A1 Self-assembling biomolecular structures
11/23/2000CA2372128A1 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals
11/23/2000CA2372119A1 Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
11/23/2000CA2372116A1 Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1b (ptp-1b)
11/23/2000CA2372098A1 Lawsonia derived gene and related flge polypeptides, peptides and proteins and their uses
11/23/2000CA2372095A1 Lawsonia derived gene and related sodc polypeptides, peptides and proteins and their uses
11/23/2000CA2371212A1 Differential gene expression in specific regions of the brain in neurodegenerative diseases
11/23/2000CA2370245A1 Enzyme-activated anti-tumor prodrug compounds
11/23/2000CA2369376A1 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for prevention of cancer in at-risk subjects
11/23/2000CA2369369A1 Buforin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins
11/23/2000CA2368833A1 Molecules expressed in hippocampus
11/23/2000CA2368624A1 Novel .beta.-secretase and modulation of .beta.-secretase activity
11/23/2000CA2368608A1 Transgenically produced antithrombin iii and mutants thereof
11/23/2000CA2368593A1 Anti-inflammatory therapy for inflammatory mediated infection
11/22/2000EP1054059A1 Novel cDNAs encoding catenin-binding proteins with function in signalling and/or gene regulation
11/22/2000EP1054058A1 Pharmaceutical composition for treatment of Duchenne muscular dystrophy
11/22/2000EP1054017A1 Salts of thrombin inhibitors
11/22/2000EP1053754A1 Method of inactivating viruses
11/22/2000EP1053751A1 Compositions and methods for treating cell proliferation disorders
11/22/2000EP1053750A1 Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis)
11/22/2000EP1053351A1 Novel molecules of the tnf receptor superfamily and uses therefor
11/22/2000EP1053332A1 Protein
11/22/2000EP1053331A2 A novel fungal protein critical for expression of fungal proteins
11/22/2000EP1053330A2 Identification, production and use of staphylokinase derivatives with reduced immunogenicity and/or reduced clearance
11/22/2000EP1053325A2 Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
11/22/2000EP1053324A1 Novel cystine knot protein and materials and methods for making it
11/22/2000EP1053323A2 Human receptor proteins
11/22/2000EP1053321A1 Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
11/22/2000EP1053320A2 Human transport-associated molecules
11/22/2000EP1053315A1 Human hairless gene, protein and uses thereof
11/22/2000EP1053313A1 Optimized antisense oligonucleotides complementary to dna methyltransferase sequences
11/22/2000EP1053308A1 Dendritic enriched secreted lymphocyte activation molecule
11/22/2000EP1053307A1 Podocalyxin like sialomucins having selectin ligand activity
11/22/2000EP1053306A1 Secreted proteins and polynucleotides encoding them
11/22/2000EP1053305A1 SUBSTRATE ANALOGS FOR MurG, METHODS OF MAKING SAME AND ASSAYS USING SAME
11/22/2000EP1053255A1 THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOF
11/22/2000EP1053254A2 COMPOSITIONS AND METHODS TO INHIBIT FORMATION OF THE C5b-9 COMPLEX OF COMPLEMENT
11/22/2000EP1053252A1 Secreted proteins and polynucleotides encoding them
11/22/2000EP1053251A1 The aiolos gene
11/22/2000EP1053249A2 Peptide inhibitors of the serine protease activity associated to the ns3 protein of hcv, relevant uses and process of production
11/22/2000EP1053247A1 Antifungal cyclohexapeptides
11/22/2000EP1053246A1 Beta-sheet mimetics and methods relating to the use thereof
11/22/2000EP1053245A1 45 human secreted proteins
11/22/2000EP1053029A1 Sterile complex of therapeutic peptide bond to a polysaccharide
11/22/2000EP1053027A1 Bibapcitide-based pharmaceutical compositions for imaging and treating thrombi
11/22/2000EP1053025A2 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
11/22/2000EP1053023A2 Systemic delivery of serum stable plasmid lipid particles for cancer therapy
11/22/2000EP1053022A2 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
11/22/2000EP1053020A1 Absorbable microparticles
11/22/2000EP1053018A2 DELIVERY OF IMMUNOGENIC MOLECULES VIA HBsAg PARTICLES
11/22/2000EP1053014A1 BIOLOGICALLY ACTIVE HEMAGGLUTININ FROM TYPE A $i(CLOSTRIDIUM BOTULINUM) AND METHODS OF USE
11/22/2000EP1053012A1 Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections
11/22/2000EP1053011A1 Mixed micellar pharmaceutical delivery system and method of preparation
11/22/2000EP1053010A1 Copolymer compositions for oral delivery
11/22/2000EP1053009A2 Use of heregulin as an epithelial cell growth factor
11/22/2000EP1053008A2 Methods of inducing hair growth and coloration
11/22/2000EP1053007A2 Methods and compositions for modulating leptin activity
11/22/2000EP1053006A1 Costimulatory blockade and mixed chimerism in transplantation
11/22/2000EP1053005A2 Method of promoting keratinocyte proliferation
1 ... 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 ... 3163